

REMARKS


Attached is a paper copy and disk copy of the new Sequence Listing. Also attached is a Statement under 37 C.F.R. § 1.821(f). The attached Sequence Listing is necessary due to the Amendment that was filed on January 31, 2004, wherein new sequence ID numbers (157-165) were designated in the "SEQ ID NO" column in the table under paragraph [00189] -- the sequence data itself, as filed, was not amended. The prior Sequence Listing only contained SEQ ID NOS 1-156; the attached Sequence Listing contains SEQ ID NOS 1-165 and contains no new matter.

In the specification, paragraphs [0042], [0051], [0071], [00200] and the Abstract have been amended to correct minor editorial problems.

It is respectfully submitted that no new matter is added and that no issues relating to patentability are raised by this Amendment. This Amendment is submitted simultaneously with payment of the issue fee. Entry of this Amendment under 37 CFR §1.312 is thus respectfully requested.

Respectfully submitted,

Date March 14, 2005

By 

EraGen Biosciences, Inc.
Customer Number: 33534
Telephone: (608) 662-9000 x345
Facsimile: (608) 662-9003

Gregory T. Pletta
Attorney for Applicants
Registration No. 47,864